We observed that IL‐33 decreased the nuclear NF‐κB p65 protein levels of MM cells in the presence of BTZ, and this phenomenon could be reversed by the intervention of anti‐IL33 or NF‐κB activator phorbol 12‐myristate 13‐acetate (PMA; Figure 4A–F). The gene discussed is IL33; the disease is Miyoshi myopathy.